Company / Net Income
MoonLake Immunotherapeutics Net Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$227.3M
FY2025
5-year range
-$227.3M / -$36.0M
FY2021-FY2025
Trend
-91.1%
vs FY2024
Sector context
#164 of 216
Health Care
What the data says
MoonLake Immunotherapeutics's net income of -$227M is lower than 76% of companies in the Health Care sector (FY2025). Declined from -$36M to -$227M over the past 2 years.
Based on SEC 10-K filings.
-$227M in FY2025.
Declined from -$36M to -$227M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 216This company -$227.3M Sector average $454.3M
▼
-150.0% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 91.1% year-over-year.
- Ranks #164 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$227.3M | -91.1% |
| FY2024 | -$118.9M | -230.3% |
| FY2023 | -$36.0M | +27.9% |
| FY2022 | -$50.0M | +6.8% |
| FY2021 | -$53.6M | -58954.2% |
| FY2020 | -$90.8K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026